

Schizophrenia Bulletin Index—1996–97

Author Index

A

Adams, Catherine; *see* Leonard, Sherry

Adler, Lawrence E.; *see* Leonard, Sherry

Agresta, Julie; *see* Mueser, Kim T.

Allen, John S. Are traditional societies schizophrenogenic?, 23(3):357–364, 1997.

Alpert, Murray; Kotsaftis, Antonis; and Pouget, Enrique R. Speech fluency and schizophrenic negative signs, 23(2):171–177, 1997.

Ammann, Roland; *see* Modestin, Jiri

Anand, Ravi; *see* Shiovitz, Thomas M.

Anonymous. First person account: Social, economic, and medical effects of schizophrenia, 22(1):183–185, 1996; First person account: The end of two roads, 23(1):163–164, 1997.

Ansel, Mark; *see* Brekke, John S.

Apperson, L. Joy; *see* McEvoy, Joseph P.

Apud, Jose; *see* Egan, Michael F.

Arnold, Steven E., and Trojanowski, John Q. Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22(1):5–9, 1996.

Aronson, Andrew; *see* Bergman, Andrea J.

Assouly-Besse, Francoise; *see* Dollfus, Sonia

B

Bachneff, Svetlozar A. Regional cerebral blood flow in schizophrenia and

the local circuit neurons hypothesis, 22(1):163–182, 1996.

Barrio, Concepcion; *see* Brekke, John S.

Barrowclough, Christine; Tarrier, Nicholas; and Johnston, Marie. Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22(4):691–702, 1996.

Battaglia, Marco, and Bellodi, Laura. Familial risks and reproductive fitness in schizophrenia, 22(2):191–195, 1996.

Battaglia, Marco; Cavallini, Maria Cristina; Macciardi, Fabio; and Bellodi, Laura. The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interview, 23(1):83–92, 1997.

Bayley, Robert. First person account: Schizophrenia, 22(4):727–729, 1996.

Bell, Morris D., and Lysaker, Paul H. Clinical benefits of paid work activity in schizophrenia: 1-year followup, 23(2):317–328, 1997.

Bell, Morris D.; Lysaker, Paul H.; and Milstein, Robert M. Clinical benefits of paid work activity in schizophrenia, 22(1):51–67, 1996.

Bellack, Alan S.; Blanchard, Jack J.; and Mueser, Kim T. Cue availability and affect perception in schizophrenia, 22(3):535–544, 1996.

Bellodi, Laura; *see* Battaglia, Marco

Benes, Francine M. What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23(3):503–507, 1997.

Benishay, Deana; *see* Raine, Adrian

Bergman, Andrea J.; Harvey, Philip D.; Mitropoulou, Vivian; Aronson, Andrew; Marder, Dova; Silverman, Jeremy; Trestman, Robert; and Siever, Larry J. The factor structure of schizotypal symptoms in a clinical population, 22(3):501–509, 1996.

Berman, Nancy; *see* Maas, James W.

Bickford, Paula; *see* Leonard, Sherry

Bird, Laura; *see* Brekke, John S.

Blanchard, Jack J.; *see* Bellack, Alan S.

Blyler, Crystal R.; *see* Fenton, Wayne S.

Bogerts, Bernhard. The temporolimbic system theory of positive schizophrenic symptoms, 23(3):423–435, 1997.

Bowden, Charles L.; *see* Maas, James W.

Braff, David L., and Swerdlow, Neal R. Neuroanatomy of schizophrenia, 23(3):509–512, 1997.

Breese, Charles R.; *see* Leonard, Sherry

Brekke, John S., and Barrio, Concepcion. Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23(2):305–316, 1997.

Brekke, John S.; Raine, Adrian; Ansel, Mark; Lenz, Todd; and Bird, Laura. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23(1):19–28, 1997.

Bromet, Evelyn; *see* Kovasznay, Beatrice

Brown, Georgia P. First person account: Paranoid schizophrenia—A sibling's story, 22(3):557–561, 1996.

Buchanan, Robert W.; *see* Conley, Robert R.

Buchanan, Robert W., and Carpenter, William T., Jr. The neuroanatomies of schizophrenia, 23(3):367–372, 1997.

Buchanan, Robert W.; Stevens, Janice R., and Carpenter, William T., Jr. The neuroanatomy of schizophrenia: Editors' introduction, 23(3):365–366, 1997.

Budd, Richard J., and Hughes, Ian C.T. What do relatives of people with schizophrenia find helpful about family intervention?, 23(2):341–347, 1997.

Buican, Brett J.; *see* Corrigan, Patrick W.

Bunk, Detlef; *see* Eggers, Christian

Byerley, William; *see* Leonard, Sherry

C

Cannon, Tyrone D.; *see* Olin, Su-chin Serene

Carpenter, William T., Jr. The risk of medication-free research, 23(1):11–18, 1997; *see also* Buchanan, Robert W.

Carr, Tom J.; *see* Stanley, Jeff A.

Carver, Lawrence; *see* Essock, Susan M.

Casanova, Manuel F. Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23(3):517–519, 1997; The temporolimbic system theory of paranoid schizophrenia, 23(3):513–515, 1997.

Casey, Daniel E.; *see* Hansen, Thomas E.

Caudle, Jane; *see* Lewine, Richard

Cavallini, Maria Cristina; *see* Battaglia, Marco

Chapman, Jean P.; *see* Kwapil, Thomas R.

Chapman, Loren J.; *see* Kwapil, Thomas R.

Claudel, Bertrand; *see* Plagnol, Arnaud

Comtois, Katherine Anne; *see* Ries, Richard K.

Conley, Robert R., and Buchanan, Robert W. Evaluation of treatment resistance in schizophrenia, 23(4):663–674, 1997.

Coon, Hilary; *see* Leonard, Sherry

Cooper, Thomas B.; *see* Volavka, Jan

Corrigan, Patrick W.; Silverman, Randy; Stephenson, James; Nugent-Hirschbeck, Joyce; and Buican, Brett J. Situational familiarity and feature recognition in schizophrenia, 22(1):153–161, 1996.

Coverdale, John H.; *see* Falloon, Ian R.H.

Crider, Andrew. Perseveration in schizophrenia, 23(1):63–74, 1997.

Crow, Timothy J. Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23(3):512–523, 1997; *see also* DeLisi, Lynn E.

Cutler, Neal R.; *see* Shiovitz, Thomas M.

Czobor, Pál, and Volavka, Jan. Positive and negative symptoms: Is their change related?, 22(4):577–590, 1996.

D

Davidson, Michael; *see* Harvey, Philip D.

de Leon, José. Smoking and vulnerability for schizophrenia, 22(3):405–409, 1996; *see also* Verghese, Cherian

Delahunty, Ann; *see* Morice, Rodney

DeLisi, Lynn E.; Sakuma, Michael; Kushner, Maureen; Finer, Daniel L.; Hoff, Anne L.; and Crow, Timothy J. Anomalous cerebral asymmetry and language processing in schizophrenia, 23(2):255–271, 1997.

Dingemans, Peter M.; *see* Linszen, Donald H.

Dohm, Faith-Anne; *see* Essock, Susan M.

Doig, Alex; *see* Gruzelier, John H.

Dollfus, Sonia; *see* Everitt, Brian; Ribeyre, Jean Marie; Assouly-Besse, Francoise; Sharp, Charlie; and Petit, Michel. Identifying subtypes of schizophrenia by cluster analyses, 22(3):545–555, 1996.

Donchin, Emanuel; *see* McCarley, Robert W.

Draine, Jeffrey; *see* Solomon, Phyllis

Drake, Robert E.; *see* Goodman, Lisa A.

Drost, Dick J.; *see* Stanley, Jeff A.

Dwork, Andrew J. Postmortem studies of the hippocampal formation in schizophrenia, 23(3):385–402, 1997.

Dykstra, Tracey. First person account: How I cope, 23(4):697–699, 1997.

E

Edwards, Jane; *see* McGorry, Patrick D.

Egan, Michael F.; Apud, Jose; and Wyatt, Richard Jed. Treatment of tardive dyskinesia, 23(4):583–609, 1997.

Eggers, Christian, and Bunk, Detlef. The long-term course of childhood-onset schizophrenia: A 42-year followup, 23(1):105–117, 1997.

Eronen, Markku; Tiihonen, Jari; and Hakola, Panu. Schizophrenia and homicidal behavior, 22(1):83–89, 1996.

Essock, Susan M.; Hargreaves, William A.; Dohm, Faith-Anne; Goethe, John; Carver, Lawrence; and Hipshman, Lawrence. Clozapine eligibility among State hospital patients, 22(1):15–25, 1996.

Everitt, Brian; *see* Dollfus, Sonia

F

Falloon, Ian R.H.; Kydd, Robert R.; Coverdale, John H.; and Laidlaw, Tannis M. Early detection and intervention for initial episodes of schizophrenia, 22(2):271–282, 1996.

Farber, Nuri B.; *see* Olney, John W.

Fenton, Wayne S.; Blyler, Crystal R.; and Heinssen, Robert K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23(4):637–651, 1997.

Fenton, Wayne S., and Kane, John

M. Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23(4):563-565, 1997.

Finer, Daniel; *see* DeLisi, Lynn E.

Fink, Max, and Sackeim, Harold A. Convulsive therapy in schizophrenia?, 22(1):27-39, 1996.

Fleischer, Jennifer; *see* Kovasznay, Beatrice

Freedman, Robert; *see* Leonard, Sherry; McCarley, Robert W.

Frith, Christopher D. Functional brain imaging and the neuropathology of schizophrenia, 23(3):525-527, 1997.

Fudge, Julie L.; *see* Haber, Suzanne N.

Funderburg, Linda G.; *see* Maas, James W.

G

George, Tony P.; *see* Ziedonis, Douglas M.

Gladsjo, Julie Akiko; *see* Jeste, Dilip V.

Godwin, Sandra; *see* McEvoy, Joseph P.

Goethe, John; *see* Essock, Susan M.

Goldberg, Joseph F.; *see* Harrow, Martin

Goldman-Rakic, Patricia S., and Selemon, Lynn D. Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23(3):437-458, 1997.

Goodman, Lisa A.; Rosenberg, Stanley D.; Mueser, Kim T.; and Drake, Robert E. Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23(4):685-696, 1997.

Gottesman, Irving I.; *see* Moldin, Steven O.

Gottesman, Irving I., and Groome, Carol S. HIV/AIDS risks as a consequence of schizophrenia, 23(4):675-684, 1997.

Gottlieb, Diane; *see* McEvoy, Joseph P.

Granger, Bernard; *see* Plagnol, Arnaud

Graybiel, Ann M. The basal ganglia and cognitive pattern generators, 23(3):459-469, 1997.

Griffith, Jay M.; *see* Leonard, Sherry Groome, Carol S.; *see* Gottesman, Irving I.

Gruzelier, John H. The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia, 22(4):611-620, 1996.

Gruzelier, John H., and Doig, Alex. The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22(4):621-634, 1996.

H

Haber, Suzanne N., and Fudge, Julie L. The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23(3):471-482, 1997.

Haden, Catherine; *see* Lewine, Richard

Hakola, Panu; *see* Eronen, Markku

Halbreich, Uriel, and Palter, Steven. Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22(3):447-454, 1996.

Halford, W. Kim; *see* Hayes, Robyn L.

Hansen, Thomas E.; Casey, Daniel E.; and Hoffman, William F. Neuroleptic intolerance, 23(4):567-582, 1997.

Hargreaves, William A.; *see* Essock, Susan M.

Harrigan, Susan M.; *see* McGorry, Patrick D.

Harrow, Martin; *see* Marengo, Joanne T.

Harrow, Martin; Sands, James R.; Silverstein, Marshall L.; and Goldberg, Joseph F. Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23(2):287-303, 1997.

Hartman, Marilyn; *see* McEvoy, Joseph P.

Hartman, Richard D.; *see* Shiovitz, Thomas M.

Harvey, Ian; *see* Takei, Noriyoshi

Harvey, Philip D.; *see* Bergman, Andrea J.

Harvey, Philip D.; Davidson, Michael; Mueser, Kim T.; Parrella, Michael; White, Leonard; and Powchik, Peter. Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23(1):131-145, 1997.

Hayes, Robyn L., and Halford, W. Kim. Time use of unemployed and employed single male schizophrenia subjects, 22(4):659-669, 1996.

Heckers, Stephan. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems, 23(3):403-421, 1997.

Heinssen, Robert K.; *see* Fenton, Wayne S.

Hipshman, Lawrence; *see* Essock, Susan M.

Hoff, Anne L.; *see* DeLisi, Lynn E.

Hoffman, William F.; *see* Hansen, Thomas E.

Horn, David; *see* Ruppin, Eytan

Hsiao, John K.; *see* McCarley, Robert W.; Shore, David

Hughes, Ian C.T.; *see* Budd, Richard J.

Hyde, Thomas M., and Weinberger, Daniel R. Seizures and schizophrenia, 23(4):611-622, 1997.

J

Jackson, Henry J.; *see* McGorry, Patrick D.; Yung, Alison R.

Jandorf, Lina; *see* Kovasznay, Beatrice

Javors, Martin A.; *see* Maas, James W.

Jeste, Dilip V.; Gladsjo, Julie Akiko; Lindamer, Laurie A.; and Lacro, Jonathan P. Medical comorbidity in schizophrenia, 22(3):413-430, 1996.

Johannessen, Jan Olav; *see* Larsen, Tor K.; McGlashan, Thomas H.

Johnston, Marie; *see* Barrowclough, Christine

Jones, Edward G. Cortical development and thalamic pathology in schizophrenia, 23(3):483-501, 1997.

Jones, Peter; *see* Takei, Noriyoshi

Josiaissen, Richard C.; *see* Verghese, Cherian

Josiaissen, Richard C., and Schindler, Barbara. Medical comorbidity and schizophrenia: Editors' introduction, 22(3):411-412, 1996.

Junginger, John. Psychosis and violence: The case for a content analysis of psychotic experience, 22(1):91-103, 1996.

K

Kane, John M.; *see* Fenton, Wayne S.; Umbrecht, Daniel

Kendler, Kenneth S.; Thacker, Leroy; and Walsh, Dermot. Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22(3):511-520, 1996.

Kosten, Therese A. Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23(2):203-213, 1997.

Kosten, Thomas R. Foreword, 23(2):179-180, 1997.

Kosten, Thomas R., and Ziedonis, Douglas M. Substance abuse and schizophrenia: Editors' introduction, 23(2):181-186, 1997.

Kotsaftis, Antonis; *see* Alpert, Murray

Kovasznay, Beatrice; Fleischer, Jennifer; Tanenberg-Karant, Marsha; Jandorf, Lina; Miller, Alan D.; and Bromet, Evelyn. Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23(2):195-201, 1997.

Kurtz, Neil M.; *see* Shiovitz, Thomas M.

Kushner, Maureen; *see* DeLisi, Lynn E.

Kwapis, Thomas R.; Chapman, Jean P.; Chapman, Loren J.; and Miller, Michael B. Deviant olfactory experiences as indicators of risk for psychosis, 22(2):371-382, 1996.

Kydd, Robert R.; *see* Falloon, Ian R.H.

L

Lacro, Jonathan P.; *see* Jeste, Dilip V.

Laidlaw, Tannis M.; *see* Falloon, Ian R.H.

Larsen, Tor K.; McGlashan, Thomas H.; and Vibe-Hansen, Lars. First-episode schizophrenia: II. Premorbid patterns by gender, 22(2):257-269, 1996.

Larsen, Tor K.; McGlashan, Thomas H.; and Moe, Lars Conrad. First-episode schizophrenia: I. Early course parameters, 22(2):241-256, 1996.

Laska, Eugene M.; *see* Volavka, Jan

Lee, Heidi; *see* Sheitman, Brian B.

Lencz, Todd; *see* Brekke, John S.; Raine, Adrian

Lenior, Marie A.; *see* Linszen, Donald H.

Leonard, Sherry; Adams, Catherine; Breese, Charles R.; Adler, Lawrence E.; Bickford, Paula; Byerley, William; Coon, Hilary; Griffith, Jay M.; Miller, Christine; Myles-Worsley, Marina; Nagamoto, Herbert T.; Rollins, Yvonne; Stevens, Karen E.; Waldo, Merilyne; and Freedman, Robert. Nicotinic receptor function in schizophrenia, 22(3):431-445, 1996.

Lewine, Richard; Haden, Catherine; Caudle, Jane; and Shurett, Rebecca. Sex-onset effects on neuropsychological function in schizophrenia, 23(1):51-61, 1997.

Lewis, David A. Schizophrenia and disordered neural circuitry, 23(3):529-531, 1997.

Lewis, Shon; *see* Takei, Noriyoshi

Lieberman, Jeffrey A.; *see* Sheitman, Brian B.

Lindamer, Laurie A.; *see* Jeste, Dilip V.

Linszen, Donald H.; Dingemans, Peter M.; Nugter, M. Annet; Van der Does, A. Jan Willem; Scholte, Willem F.; and Lenior, Marie A. Patient attributes and expressed emotion as risk factors for psychotic relapse, 23(1):119-130, 1997.

Lysaker, Paul H.; *see* Bell, Morris D.

M

Maas, James W.; Bowden, Charles L.; Miller, Alexander L.; Javors, Martin A.; Funderburg, Linda G.; Berman, Nancy; and Weintraub, Susan T. Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23(1):147-154, 1997.

Macciardi, Fabio; *see* Battaglia, Marco

Malla, Ashok; *see* Stanley, Jeff A.

Mannion, Edie; *see* Solomon, Phyllis Marder, Dova; *see* Bergman, Andrea J.

Marengo, Joanne T., and Harrow, Martin. Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23(2):273-285, 1997.

Mattes, Jeffrey A. Risperidone: How good is the evidence for efficacy?, 23(1):155-161, 1997.

McCarley, Robert W.; Hsiao, John K.; Freedman, Robert; Pfefferbaum, Adolf; and Donchin, Emanuel. Neuroimaging and the cognitive neuroscience of schizophrenia, 22(4):703-725, 1996.

McEvoy, Joseph P.; Hartman, Marilyn; Gottlieb, Diane; Godwin, Sandra; Apperson, L. Joy; and Wilson, William. Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22(4):635-641, 1996.

McFarlane, Colleen A.; *see* Yung, Alison R.

McGeer, Patrick L.; *see* Oken, Robert J.

McGlashan, Thomas H. Early detection and intervention in schizophrenia: Editors' introduction, 22(2):197-199, 1996; Early detection and intervention in schizophrenia: Research, 22(2):327-345, 1996; *see also* Larsen, Tor K.

McGlashan, Thomas H., and Johannessen, Jan Olav. Early detection and intervention with schizophrenia: Rationale, 22(2):201-222, 1996.

McGorry, Patrick D.; *see* Yung, Alison R.

McGorry, Patrick D.; Edwards, Jane; Mihalopoulos, Cathrine; Harrigan, Susan M.; and Jackson, Henry J. EPPIC: An evolving system of early detection and optimal management, 22(2):305-326, 1996.

Mednick, Sarnoff A.; *see* Olin, Su-chin Serene

Meisel, Marilyn; *see* Solomon, Phyllis

Meisner, Morris; *see* Volavka, Jan

Mihalopoulos, Cathrine; *see* McGorry, Patrick D.

Miller, Alan D.; *see* Kovasznay, Beatrice

Miller, Alexander L.; *see* Maas, James W.

Miller, Christine; *see* Leonard, Sherry

Miller, Laura J. Sexuality, reproduction, and family planning in women with schizophrenia, 23(4):623-635, 1997.

Miller, Michael B.; *see* Kwapil, Thomas R.

Milstein, Robert M.; *see* Bell, Morris D.

Miner, Christian R.; *see* Rosenthal, Richard N.

Mitropoulou, Vivian; *see* Bergman, Andrea J.

Modestin, Jiri, and Ammann, Roland. Mental disorder and criminality: Male schizophrenia, 22(1):69-82, 1996.

Moe, Lars Conrad; *see* Larsen, Tor K.

Moldin, Steven O., and Gottesman, Irving I. Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23(4):547-561, 1997.

Molta, Victoria E. First person account: Living with mental illness, 23(2):349-351, 1997.

Morice, Rodney, and Delahunty, Ann. Frontal/executive impairments in schizophrenia, 22(1):125-137, 1996.

Mueser, Kim T.; *see* Bellack, Alan S.; Goodman, Lisa A.; Harvey, Philip D.

Mueser, Kim T.; Valentiner, David P.; and Agresta, Julie. Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23(2):329-339, 1997.

Murphy, Marcia A. First person account: Meaning of psychoses, 23(3):541-543, 1997.

Murray, Robin M.; *see* Takei, Noriyoshi

Myles-Worsley, Marina; *see* Leonard, Sherry

Nagamoto, Herbert T.; *see* Leonard, Sherry

Nugent-Hirschbeck, Joyce; *see* Corrigan, Patrick W.

Nugter, M. Annet; *see* Linszen, Donald H.

Oken, Robert J., and McGeer, Patrick L. Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22(1):1-4, 1996.

Olin, Su-chin Serene, and Mednick, Sarnoff A. Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22(2):223-240, 1996.

Olin, Su-chin Serene; Raine, Adrian; Cannon, Tyrone D.; Parnas, Josef; Schulsinger, Fini; and Mednick, Sarnoff A. Childhood behavior precursors of schizotypal personality disorder, 23(1):93-103, 1997.

Olney, John W., and Farber, Nuri B. Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23(3):533-536, 1997.

Pachoud, Bernard; *see* Plagnol, Arnaud

Palter, Steven; *see* Halbreich, Uriel

Parnas, Josef; *see* Olin, Su-chin Serene

Parrella, Michael; *see* Harvey, Philip D.

Patton, George C.; *see* Yung, Alison R.

Petit, Michel; *see* Dollfus, Sonia

Pfefferbaum, Adolf; *see* McCarley, Robert W.

Plagnol, Arnaud; Pachoud, Bernard; Claudel, Bertrand; and Granger, Bernard. Functional disorganization of representations in schizophrenia, 22(2):383-398, 1996.

Pouget, Enrique R.; *see* Alpert, Murray

Powchik, Peter; *see* Harvey, Philip D.

R

Raine, Adrian; *see* Brekke, John S.; Olin, Su-chin Serene

Raine, Adrian; Benishay, Deana; Lencz, Todd; and Scarpa, Angela. Abnormal orienting in schizotypal personality disorder, 23(1):75-82, 1997.

Rakkar, Arun; *see* Yung, Alison R.

Reggia, James A.; *see* Ruppin, Eytan

Ribeyre, Jean Marie; *see* Dollfus, Sonia

Ries, Richard K., and Comtois, Katherine Anne. Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23(2):239-246, 1997.

Robeson, Mary R.; *see* Sanguineti, Vincenzo R.

Rollins, Yvonne; *see* Leonard, Sherry

Rombouts, René P.; *see* van den Bosch, Robert J.

Rosenberg, Stanley D.; *see* Goodman, Lisa A.

Rosenthal, Richard N., and Miner, Christian R. Differential diagnosis of substance-induced psychosis and schizophrenia in patients with sub-

stance use disorder, 23(2):187-193, 1997.

Ruppin, Eytan; Reggia, James A.; and Horn, David. Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22(1):105-123, 1996.

Rylett, R. Jane; *see* Stanley, Jeff A.

S

Sackheim, Harold A.; *see* Fink, Max

Sakuma, Michael; *see* DeLisi, Lynn E.

Samuel, Steven E.; *see* Sanguineti, Vincenzo R.

Sands, James R.; *see* Harrow, Martin

Sanguineti, Vincenzo R.; Samuel, Steven E.; Schwartz, Stephen L.; and Robeson, Mary R. Gender differences among civilly committed schizophrenia subjects, 22(4):653-658, 1996.

Scarpa, Angela; *see* Raine, Adrian

Schindler, Barbara; *see* Josiassen, Richard C.

Scholte, Willem F.; *see* Linszen, Donald H.

Schulsinger, Fini; *see* Olin, Su-chin Serene

Schwartz, Stephen L.; *see* Sanguineti, Vincenzo R.

Selemon, Lynn D.; *see* Goldman-Rakic, Patricia S.

Sewell, Daniel D. Schizophrenia and HIV, 22(3):465-473, 1996.

Sharp, Charlie; *see* Dollfus, Sonia

Sheitman, Brian B.; Lee, Heidi; Strauss, Rael; and Lieberman, Jeffrey A. The evaluation and treatment of first-episode psychosis, 23(4):653-661, 1997.

Shiovitz, Thomas M.; *see* Welke, Timothy L.; Tigel, Phillip D.; Anand, Ravi; Hartman, Richard D.; Sramek, John J.; Kurtz, Neil M.; and Cutler, Neal R. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, 22(4):591-595, 1996.

Shore, David, and Hsiao, John K. Medication-free intervals and schizophrenia research: Editors' introduction, 23(1):1, 1997.

Shurett, Rebecca; *see* Lewine, Richard

Siever, Larry J.; *see* Bergman, Andrea J.

Silverman, Jeremy; *see* Bergman, Andrea J.

Silverman, Randy; *see* Corrigan, Patrick W.

Silverstein, Marshall L.; *see* Harrow, Martin

Simpson, John C., and Tsuang, Ming T. Mortality among patients with schizophrenia, 22(3):485-499, 1996.

Solomon, Phyllis; Draine, Jeffrey; Mannion, Edie; and Meisel, Marilyn. Impact of brief family psychoeducation on self-efficacy, 22(1):41-50, 1996.

Spitzer, Manfred. A cognitive neuroscience view of schizophrenic thought disorder, 23(1):29-50, 1997.

Sramek, John J.; *see* Shiovitz, Thomas M.

Stanley, Jeff A.; Williamson, Peter C.; Drost, Dick J.; Rylett, R. Jane; Carr, Tom J.; Malla, Ashok; and Thompson, R. Terry. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients, 22(4):597-609, 1996.

Stephenson, James; *see* Corrigan, Patrick W.

Stevens, Janice R. Anatomy of schizophrenia revisited, 23(3):373-383, 1997; *see also* Buchanan, Robert W.

Stevens, Karen E.; *see* Leonard, Sherry

Strauss, Rael; *see* Sheitman, Brian B.

Swerdlow, Neal R.; *see* Briff, David L.

T

Takei, Noriyoshi; Lewis, Shon; Jones, Peter; Harvey, Ian; and Murray, Robin M. Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22(3):521-534, 1996.

Tanenberg-Karant, Marsha; *see* Kovasznay, Beatrice

Terrier, Nicholas; *see* Barrowclough, Christine

Thacker, Leroy; *see* Kendler, Kenneth S.

Thompson, R. Terry; *see* Stanley, Jeff A.

Tigel, Phillip D.; *see* Shiovitz, Thomas M.

Tiihonen, Jari; *see* Eronen, Markku

Trestman, Robert; *see* Bergman, Andrea J.

Trojanowski, John Q.; *see* Arnold, Steven E.

Trudeau, Kimberlee; *see* Ziedonis, Douglas M.

Tsuang, Ming T.; *see* Simpson, John C.

U

Umbrecht, Daniel, and Kane, John M. Medical complications of new antipsychotic drugs, 22(3):475-483, 1996.

V

Vaglum, Per. Earlier detection and intervention in schizophrenia: Unsolved questions, 22(2):347-351, 1996.

Valentiner, David P.; *see* Mueser, Kim T.

van Asma, Maria J.O.; *see* van den Bosch, Robert J.

van den Bosch, Robert J.; Rombouts, René P.; and van Asma, Maria J.O. What determines Continuous Performance Task performance?, 22(4):643-651, 1996.

Van der Does, A. Jan Willem; *see* Linszen, Donald H.

Vergheze, Cherian; de Leon, José; and Josiassen, Richard C. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22(3):455-464, 1996.

Vibe-Hansen, Lars; *see* Larsen, Tor K.

Volavka, Jan; *see* Czobor, Pál

Volavka, Jan; Cooper, Thomas B.; Laska, Eugene M.; and Meisner, Morris. Placebo washout in trials of antipsychotic drugs, 22(4):567-576, 1996.

W

Wagner, Pamela Spiro. First person account: A voice from another closet, 22(2):399-401, 1996.

Waldo, Merilyn; *see* Leonard, Sherry

Walsh, Dermot; *see* Kendler, Kenneth S.

Weinberger, Daniel R. On localizing schizophrenic neuropathology, 23(3):537-540, 1997; *see also* Hyde, Thomas M.

Weintraub, Susan T.; *see* Maas, James W.

Welke, Timothy L.; *see* Shiovitz, Thomas M.

White, Leonard; *see* Harvey, Philip D.

Wilkins, Jeffery N. Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23(2):215-228, 1997.

Williams, Leanne M. Cognitive inhibition and schizophrenic symptom subgroups, 22(1):139-151, 1996.

Williamson, Peter C.; *see* Stanley, Jeff A.

Wilson, William; *see* McEvoy, Joseph P.

Wuerker, Anne McCarrick. Communication patterns and expressed emotion in families of persons with mental disorders, 22(4):671-690, 1996.

Wyatt, Richard Jed. Research in schizophrenia and the discontinuation of antipsychotic medications, 23(1):3-9, 1997; *see also* Egan, Michael F.

Y

Yung, Alison R., and McGorry, Patrick D. The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22(2):353-370, 1996.

Yung, Alison R.; McGorry, Patrick D.; McFarlane, Colleen A.;

Jackson, Henry J.; Patton, George C.; and Rakkar, Arun. Monitoring and care of young people at incipient risk of psychosis, 22(2):283-303, 1996.

Z

Ziedonis, Douglas M.; *see* Kosten, Thomas R.

Ziedonis, Douglas M., and George, Tony P. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23(2):247-254, 1997.

Ziedonis, Douglas M., and Trudeau, Kimberlee. Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23(2):229-238, 1997.

Subject Index

A

Acquired immunodeficiency syndrome
HIV/AIDS risks as a consequence of schizophrenia, 23:675

Adaptive functioning

Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131

Affect perception

Cue availability and affect perception in schizophrenia, 22:535

Affective disorders

Mortality among patients with schizophrenia, 22:485

The prodromal phase of first-episode

psychosis: Past and current conceptualizations, 22:353

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Age factors

Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447

Childhood behavior precursors of schizotypal personality disorder, 23:93

Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

Convulsive therapy in schizophrenia?, 22:27

Medical comorbidity in schizophrenia, 22:413

Monitoring and care of young people at incipient risk of psychosis, 22:283

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131

AIDS. *See* Acquired immunodeficiency syndrome

Alcohol

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Pharmacotherapy of schizophrenia

patients with comorbid substance abuse, 23:215

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Alcoholism

Schizophrenia and homicidal behavior, 22:83

Alogia

Speech fluency and schizophrenic negative signs, 23:171

Alphabet Span

Frontal/executive impairments in schizophrenia, 22:125

Alzheimer's disease. See also Dementia

Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Schizophrenia and disordered neural circuitry, 23:529

Amphetamine

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Amygdala. See Neuroanatomy

Anthropology

At issue: Are traditional societies schizophrenogenic?, 23:359

Anti-inflammatory drugs

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Anticonvulsants

Seizures and schizophrenia, 23:359

Antipsychotic drugs. See also Neuroleptics; Treatment

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

The evaluation and treatment of first-episode psychosis, 23:653

Evaluation of treatment-resistant schizophrenia, 23:663

Medical complications of new antipsychotic drugs, 22:475

Medication-free intervals and schizophrenia research: Editors' introduction, 23:1

Placebo washout in trials of antipsychotic drugs, 22:567

Research in schizophrenia and the discontinuation of antipsychotic medications, 23:3

The risk of medication-free research, 23:11

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Arousal

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Association studies

At issue: Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Attention dysfunctions

Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Auditory gating

Nicotinic receptor function in schizophrenia, 22:431

B

Basal ganglia. See Neuropathology

Behavior

Childhood behavior precursors of schizotypal personality disorder, 23:93

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

Perseveration in schizophrenia, 23:63

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Situational familiarity and feature recognition in schizophrenia, 22:153

Bipolar disorders

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Bone mineral density

Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447

Brain areas. See Neuroanatomy; Neuropathology

Brain asymmetry. See Cerebral asymmetry

Brain development

Seizures and schizophrenia, 23:611

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

Brain morphology

Anatomy of schizophrenia revisited, 23:373

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Cortical development and thalamic pathology in schizophrenia, 23:483

What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503

Brief Psychiatric Rating Scale

Patient attributes and expressed emo-

tion as risk factors for psychotic relapse, 23:119

Positive and negative symptoms: Is their change related?, 22:577

C

Cancer
Medical comorbidity in schizophrenia, 22:413

Cannabis. See Marijuana

Cardiac side effects
Neuroleptic intolerance, 23:567

Caregivers
Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22:691

Carmel Workshop on Cognitive Psychophysiology
Neuroimaging and the cognitive neuroscience of schizophrenia, 22:703

Catatonia
Convulsive therapy in schizophrenia?, 22:27

Cerebral asymmetry
Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Cerebral cortex. See Neuroanatomy; Neuropathology

Cerebrospinal fluid
Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Childhood onset. See also Age factors
The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Classification
Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Clozapine
Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, 22:591

Clozapine eligibility among State hospital patients, 22:15

Medical complications of new antipsychotic drugs, 22:475

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Cluster analysis
Identifying subtypes of schizophrenia by cluster analyses, 22:545

Cocaine
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Cognition
Functional brain imaging and the neuropathology of schizophrenia, 23:525

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Cognitive impairment
Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

Cognitive inhibition and schizophrenic symptom subgroups, 22:139

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Frontal/executive impairments in schizophrenia, 22:125

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:525

Functional disorganization of representations in schizophrenia, 22:383

Medical comorbidity in schizophrenia, 22:413

Neuroimaging and the cognitive neuroscience of schizophrenia, 22:703

Perseveration in schizophrenia, 23:63

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Situational familiarity and feature recognition in schizophrenia, 22:153

What determines Continuous Performance Task performance?, 22:643

Cognitive neuroscience
A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Cognitive planning
The basal ganglia and cognitive pattern generators, 23:459

Commitment status
Gender differences among civilly committed schizophrenia subjects, 22:653

Common sense

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Communication patterns

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Community functioning

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Time use of unemployed and employed single male schizophrenia subjects, 22:659

Comorbidity. See also Substance abuse

Medical comorbidity and schizophrenia: Editors' introduction, 22:411

Medical comorbidity in schizophrenia, 22:413

Schizophrenia and HIV, 22:465

Computerized imaging. See Magnetic resonance imaging; Magnetic resonance spectroscopy; Positron emission tomography; Single photon emission tomography

Concreteness

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Contingency management

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Continuous Performance Task

What determines Continuous Performance Task performance?, 22:643

Controlled Word Association Test

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Coping strategies

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

First person account: How I cope, 23:697

First person account: Living with mental illness, 23:349

Corpus callosum. See Neuropathology

Cortical circuitry. See Neural circuits

Course and outcome

Anatomy of schizophrenia revisited, 23:373

Clinical benefits of paid work activity in schizophrenia, 22:51

Clinical benefits of paid work activity in schizophrenia: 1-year followup, 23:317

Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Early detection and intervention in schizophrenia: Research, 22:327

First-episode schizophrenia: I. Early course parameters, 22:241

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

First person account: A voice from another closet, 22:399

First person account: Living with mental illness, 23:349

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Medication-free intervals and schizophrenia research: Editors' introduction, 23:1

Research in schizophrenia and the discontinuation of antipsychotic medications, 23:3

The risk of medication-free research, 23:11

Schizophrenia and HIV, 22:465

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Criminality. See also Violence

Mental disorder and criminality: Male schizophrenia, 22:69

Schizophrenia and homicidal behavior, 22:83

Cultural factors

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

D

Delay of treatment

First-episode schizophrenia: I. Early course parameters, 22:241

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

Delusional disorder

Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorder, 23:187

Delusions

First person account: The end of two roads, 23:163

Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105

Dementia. See also Alzheimer's disease

Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

Medical comorbidity in schizophrenia, 22:413

Demographic factors

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Depression

Mortality among patients with schizophrenia, 22:485

What determines Continuous Performance Task performance?, 22:643

Dermatologic side effects
Neuroleptic intolerance, 23:567

Desipramine
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Digits Span Forward
Frontal/executive impairments in schizophrenia, 22:125

Disability
Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

Disability Assessment Schedule
The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Dopamine
The basal ganglia and cognitive pattern generators, 23:459
A cognitive neuroscience view of schizophrenic thought disorder, 23:29
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203
Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517
Functional brain imaging and the neuropathology of schizophrenia, 23:525
The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215
Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Drug discrimination
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Dual diagnosis. See Substance abuse

E

Early detection and intervention
Earlier detection and intervention in schizophrenia: Unsolved questions, 22:347
Early detection and intervention for initial episodes of schizophrenia, 22:271
Early detection and intervention in schizophrenia: Editor's introduction, 22:197
Early detection and intervention in schizophrenia: Research, 22:327
Early detection and intervention with schizophrenia: Rationale, 22:201
EPPIC: An evolving system of early detection and optimal management, 22:305
The evaluation and treatment of first-episode psychosis, 23:653

Early Psychosis Prevention and Intervention Centre
EPPIC: An evolving system of early detection and optimal management, 22:305

Early stages of psychosis. See First-episode psychosis

Economic factors. See Socioeconomic factors

Efficacy
Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

Elderly persons. See Age factors

Electroconvulsive therapy
Convulsive therapy in schizophrenia, 22:27

Employment
Clinical benefits of paid work activity in schizophrenia, 22:51
Clinical benefits of paid work activ-

ity in schizophrenia: 1-year followup, 23:317
Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19
Time use of unemployed and employed single male schizophrenia subjects, 22:659

Environmental factors
Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637
Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Epidemiology
The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229
Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521
Schizophrenia and homicidal behavior, 22:83

Epilepsy
Anatomy of schizophrenia revisited, 23:373
Seizures and schizophrenia, 23:611

Ethical issues
Research in schizophrenia and the discontinuation of antipsychotic medications, 23:11
The risk of medication-free research, 23:11

Ethnicity
Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Event-related potentials
A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Evolution

Are traditional societies schizophrenic?, 23:357

Expressed emotion

Are traditional societies schizophrenic?, 23:357

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22:691

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Extrapyramidal side effects

Medical complications of new anti-psychotic drugs, 22:475

Neuroleptic intolerance, 23:567

Seizures and schizophrenia, 23:611

Treatment of tardive dyskinesia, 23:583

F

Factor analysis

The factor structure of schizotypal symptoms in a clinical population, 22:501

The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia, 22:611

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Occupations, factors, and schizophrenia, 22:11

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Families

Communication patterns and expressed emotion in families of

persons with mental disorders, 22:671

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22:691

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Impact of brief family psychoeducation on self-efficacy, 22:41

Family intervention

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

What do relatives of people with schizophrenia find helpful about family intervention?, 23:341

Family planning issues

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Family studies

Familial risks and reproductive fitness in schizophrenia, 22:191

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

Fertility

Familial risks and reproductive fitness in schizophrenia, 22:191

First-episode psychosis

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

Early detection and intervention for initial episodes of schizophrenia, 22:271

Early detection and intervention in schizophrenia: Research, 22:327

Early detection and intervention with schizophrenia: Rationale, 22:201

The evaluation and treatment of first-episode psychosis, 23:653

First-episode schizophrenia: I. Early course parameters, 22:241

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22:353

Sex-onset effects on neuropsychological function in schizophrenia, 23:51

Flat affect

Speech fluency and schizophrenic negative signs, 23:171

Fluency

Speech fluency and schizophrenic negative signs, 23:171

Frontal/executive impairments

Frontal/executive impairments in schizophrenia, 22:125

Frontal lobes. *See* Neuropathology

Functional connectivity

Cortical development and thalamic pathology in schizophrenia, 23:483

Functional brain imaging and the neuropathology of schizophrenia, 23:437, 517

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

G

GABA. *See* Gamma-aminobutyric acid

Gamma-aminobutyric acid

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

Gender factors

The factorial structure of schizotypy: Part II. Cognitive asymmetry,

arousal, handedness, and sex, 22:621

Gender differences among civilly committed schizophrenia subjects, 22:653

HIV/AIDS risks as a consequence of schizophrenia, 23:675

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Mental disorder and criminality: Male schizophrenia, 22:69

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Sex-onset effects on neuropsychological function in schizophrenia, 23:51

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Time use of unemployed and employed single male schizophrenia subjects, 22:659

Genetic factors

Early detection and intervention with schizophrenia: Rationale, 22:201

Familial risks and reproductive fitness in schizophrenia, 22:191

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Medical comorbidity and schizophrenia: Editors' introduction, 22:411

Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Substance abuse and schizophrenia: Editor's introduction, 23:181

Geriatric patients. See Age factors

Global Assessment of Functioning

First-episode schizophrenia: I. Early course parameters, 22:241

Glutamate

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients, 22:597

Grants

Schizophrenia-related grants—Fiscal year 1995, 22:731

H

Hallucinations. See also Olfactory hallucinations

First person account: The end of two roads, 23:163

Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105

Hallucinosis

Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorder, 23:187

Hand skill

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Handedness

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Hepatic dysfunction

Neuroleptic intolerance, 23:567

Heterogeneity

Anatomy of schizophrenia revisited, 23:373

Hippocampus. See Neuroanatomy

HIV. See Human immunodeficiency virus

Homicide. See also Violence

Schizophrenia and homicidal behavior, 22:83

Homosexuality

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Homovanillic acid

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Hospitalization

Gender differences among civilly committed schizophrenia subjects, 22:653

Human immunodeficiency virus

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Schizophrenia and HIV, 22:465

Hyponatremia

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Hypotension

Medical complications of new antipsychotic drugs, 22:475

I

Influenza

Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Information processing. See also Cognition

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Perseveration in schizophrenia, 23:63

Insight and Treatment Attitudes Questionnaire

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Instrument for the Retrospective Assessment of Onset of Schizophrenia
The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Intelligence
Are traditional societies schizophrenogenic?, 23:357

Frontal/executive impairments in schizophrenia, 22:125

Interviews
The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

L

L-Dopa
A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Language
Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

Limbic system
Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

On localizing schizophrenic neuropathology, 23:537

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

The temporolimbic system theory of paranoid schizophrenia, 23:513

M

Magical Ideation Scale
Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Magnetic resonance imaging
Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Magnetic resonance spectroscopy
An *in vivo* proton magnetic resonance spectroscopy study of schizophrenia patients, 22:597

Marijuana
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Medical comorbidity. See Comorbidity

Memory. See Cognitive impairment

Minority groups
Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Modulation
Functional brain imaging and the neuropathology of schizophrenia, 23:525

Mortality risk
Mortality among patients with schizophrenia, 22:485

Motivation
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Motivational enhancement therapy
Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Motor planning
The basal ganglia and cognitive pattern generators, 23:459

N

N-methyl-D-aspartate

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Negative priming

Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Negative signs

Speech fluency and schizophrenic negative signs, 23:171

Negative symptoms

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

Evaluation of treatment-resistant schizophrenia, 23:663

Identifying subtypes of schizophrenia by cluster analyses, 22:545

The neuroanatomies of schizophrenia, 23:367

Positive and negative symptoms: Is their change related?, 22:577

Substance abuse and schizophrenia: Editor's introduction, 23:181

Neural circuits

The neuroanatomies of schizophrenia, 23:367

The neuroanatomy of schizophrenia: Editors' introduction, 23:365

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Schizophrenia and disordered neural circuitry, 23:529

What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503

Neural modeling

Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105

Neural networks

Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:525

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

The neuroanatomies of schizophrenia, 23:367

Neuroanatomy of schizophrenia, 23:509

The neuroanatomy of schizophrenia: Editors' introduction, 23:565

Postmortem studies of the hippocampal formation in schizophrenia, 23:385

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Neurobiology

Evaluation of treatment-resistant schizophrenia, 23:663

Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Neuroimaging. See also specific imaging techniques

Neuroimaging and the cognitive neuroscience of schizophrenia, 22:703

Neuroleptic malignant syndrome

Medical complications of new anti-psychotic drugs, 22:475

Neuroleptic intolerance, 23:567

Neuroleptics. See also Antipsychotic drugs; also specific drugs by name

Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Seizures and schizophrenia, 23:611

Temporal limbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

Medical comorbidity in schizophrenia, 22:413

Neuroleptic intolerance, 23:567

Risperidone: How good is the evidence for efficacy?, 23:155

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Schizophrenia and HIV, 22:465

Seizures and schizophrenia, 23:611

Treatment of tardive dyskinesia, 23:583

Neurologic side effects

Neuroleptic intolerance, 23:567

Neuropathology. See also Neuroanatomy

Anatomy of schizophrenia revisited, 23:373

The basal ganglia and cognitive pattern generators, 23:459

Cortical development and thalamic pathology in schizophrenia, 23:483

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

Functional brain imaging and the neuropathology of schizophrenia, 23:525

On localizing schizophrenic neuropathology, 23:537

The neuroanatomies of schizophrenia, 23:367

The neuroanatomy of schizophrenia: Editors' introduction, 23:365

Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems, 23:403

Postmortem studies of the hippocampal formation in schizophrenia, 23:385

Schizophrenia and disordered neural circuitry, 23:529

Seizures and schizophrenia, 23:611

Temporal limbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

The temporolimbic system theory of paranoid schizophrenia, 23:513

The temporolimbic system theory of positive schizophrenic symptoms, 23:423

What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503

Neuropsychology

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Neurotoxicity

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

Nicotine

Medical comorbidity in schizophrenia, 22:413

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Nicotine dependence

Nicotinic receptor function in schizophrenia, 22:431

Schizophrenia and nicotine use:

Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Smoking and vulnerability for schizophrenia, 22:405

Nitric oxide

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

NMDA. *See N-methyl-D-aspartate*

O

Ocular side effects

Neuroleptic intolerance, 23:567

Olfactory hallucinations

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Scale for rating olfactory hallucinations and other olfactory experiences, 22:381

Onset of psychosis. *See First-episode psychosis*

Opiates

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Opioids

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Osteoporosis

Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447

Outcome. *See Course and outcome*

P

PANSS. *See Positive and Negative Syndrome Scale*

Paranoia

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

The temporolimbic system theory of paranoid schizophrenia, 23:513

The temporolimbic system theory of positive schizophrenic symptoms, 23:423

Paranoid schizophrenia

First person account: Paranoid schizophrenia—A sibling's story, 22:557

Parenting issues

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Perceptual Aberration Scale

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Perseveration

Perseveration in schizophrenia, 23:63

PET scans. *See Positron emission tomography*

Pharmacotherapy. *See also specific drugs and classes of drugs by name*

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

The evaluation and treatment of first-episode psychosis, 23:653

Evaluation of treatment-resistant schizophrenia, 23:663

First person account: Meaning of psychoses, 23:541

Foreword, 23:179

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Neuroleptic intolerance, 23:567

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Seizures and schizophrenia, 23:611

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Substance abuse and schizophrenia: Editor's introduction, 23:181

Treatment of tardive dyskinesia, 23:583

Place conditioning

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Placebo

Placebo washout in trials of antipsychotic drugs, 22:567

Polydipsia

Medical comorbidity in schizophrenia, 22:413

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Polyuria
Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Positive and Negative Syndrome Scale
First-episode schizophrenia: I. Early course parameters, 22:241
Identifying subtypes of schizophrenia by cluster analyses, 22:545

Positive symptoms
Identifying subtypes of schizophrenia by cluster analyses, 22:545
The neuroanatomies of schizophrenia, 23:367
Positive and negative symptoms: Is their change related?, 22:577
The temporolimbic system theory of positive schizophrenic symptoms, 23:423

Positron emission tomography
Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Postmortem studies
The neuroanatomy of schizophrenia: Editors' introduction, 23:365
Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems, 23:403
Postmortem studies of the hippocampal formation in schizophrenia, 23:385

Pregnancy. See Prenatal infections; Reproductive issues; Viral infections

Premorbid Adjustment Scale
First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

Prenatal infections. See also Viral infections

Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Present State Examination
The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Primates
Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517
The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

Process analysis
What do relatives of people with schizophrenia find helpful about family intervention?, 23:341

Prodromal phase
Earlier detection and intervention in schizophrenia: Unsolved questions, 22:347
Early detection and intervention in schizophrenia: Research, 22:327
Monitoring and care of young people at incipient risk of psychosis, 22:283
The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22:353

Psilocybin
A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Psychoeducation
Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329
Impact of brief family psychoeducation on self-efficacy, 22:41

Psychopharmacology. See Pharmacotherapy

Psychoses. See also First-episode psychosis

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Convulsive therapy in schizophrenia?, 22:27

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

First person account: Meaning of psychoses, 23:541

Psychosis and violence: The case for a content analysis of psychotic experience, 22:91

Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Psychosocial functioning
Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Psychosocial treatment
Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Psychotherapy
Foreword, 23:179
Substance abuse and schizophrenia: Editors' introduction, 23:181

Psychotic disorders
Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

R

rCBF. *See* Regional cerebral blood flow

Reaction time

What determines Continuous Performance Task performance?, 22:643

Regional cerebral blood flow

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Relapse prediction

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Relapse prevention

Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Relational Control Coding System

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Relatives. *See* Families; Siblings

Representations

Functional disorganization of representations in schizophrenia, 22:383

Reproductive issues

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

Familial risks and reproductive fitness in schizophrenia, 22:191

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Respiratory side effects

Neuroleptic intolerance, 23:567

Rheumatoid arthritis

Medical comorbidity in schizophrenia, 22:413

Risk factors. *See also* Vulnerability factors

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Early detection and intervention with schizophrenia: Rationale, 22:201

Familial risks and reproductive fitness in schizophrenia, 22:191

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Monitoring and care of young people at incipient risk of psychosis, 22:283

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Seizures and schizophrenia, 23:611

Risperidone

Medical complications of new antipsychotic drugs, 22:475

Risperidone: How good is the evidence for efficacy?, 23:155

S

SAFE. *See* Social-Adaptive Functioning Evaluation

Scales

Scale for rating olfactory hallucinations and other olfactory experiences, 22:371

Scales for the Assessment of Positive and Negative Symptoms

Positive and negative symptoms: Is their change related?, 22:577

Schedule for the Assessment of Negative Symptoms, 22:139

Schedule for the Assessment of Positive Symptoms, 22:139

Schizoaffective disorder

Clozapine eligibility among State hospital patients, 22:15

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Schizotypal personality disorder

Abnormal orienting in schizotypal personality disorder, 23:75

Childhood behavior precursors of schizotypal personality disorder, 23:93

The factor structure of schizotypal symptoms in a clinical population, 22:501

Familial risks and reproductive fitness in schizophrenia, 22:191

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Schizotypal Personality Questionnaire

Abnormal orienting in schizotypal personality disorder, 23:75

Schizotypy

The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia, 22:611

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Occupations, factors, and schizophrenia, 22:11

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

SCOR

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Seizures

Seizures and schizophrenia, 23:611

Self-monitoring

Functional brain imaging and the neuropathology of schizophrenia, 23:437, 517

Self-reports

Self-report measures of schizotypy

as indices of familial vulnerability to schizophrenia, 22:511

Semantic priming
A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Sensory deficits
Medical comorbidity in schizophrenia, 22:413
Nicotinic receptor function in schizophrenia, 22:431

Sentence Span
Frontal/executive impairments in schizophrenia, 22:125

Serotonin
Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Severe mental illness
Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Sexual dysfunction
Neuroleptic intolerance, 23:567
Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Sexuality issues
Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563
HIV/AIDS risks as a consequence of schizophrenia, 23:675
Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685
Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

SFRT-2. See Situational Feature Recognition Test, Version 2

Siblings
Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Side effects
Medical complications of new antipsychotic drugs, 22:475
Neuroleptic intolerance, 23:567

Signal-to-noise ratio
A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Single photon emission tomography
Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Situational Feature Recognition Test, Version 2
Situational familiarity and feature recognition in schizophrenia, 22:153

Skin conductance
Abnormal orienting in schizotypal personality disorder, 23:75
Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Smoking
Medical comorbidity in schizophrenia, 22:413
Nicotinic receptor function in schizophrenia, 22:431
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215
Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247
Smoking and vulnerability for schizophrenia, 22:405

Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131

Social class. See Demographic factors

Social functioning. See also Psychosocial functioning
Are traditional societies schizophrenogenic?, 23:357
Cue availability and affect perception in schizophrenia, 22:535
Early detection and intervention for initial episodes of schizophrenia, 22:271
Occupations, factors, and schizophrenia, 22:11
Situational familiarity and feature recognition in schizophrenia, 22:153

Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131

Time use of unemployed and employed single male schizophrenia subjects, 22:659

Social Knowledge Questionnaire
Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Sociocentric indicators
Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Socioeconomic factors
Clinical benefits of paid work activity in schizophrenia, 22:51
First person account: Social, economic, and medical effects of schizophrenia, 22:183
Occupations, factors, and schizophrenia, 22:11

Speciation
Temporal limbic or transcallosal connections: Where is the primary

lesion in schizophrenia and what is its nature?, 23:521

Speech generation
Speech fluency and schizophrenic negative signs, 23:171

Stereotypy
The basal ganglia and cognitive pattern generators, 23:459
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Stimulants
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Striatum. See Neuroanatomy; Neuropathology

Stroop test
Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Structured Interview for DSM-III-R Personality Disorders
The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Subjective experiences
First person account: A voice from another closet, 22:399
First person account: How I cope, 23:697
First person account: Living with mental illness, 23:349
First person account: Meaning of psychoses, 23:541
First person account: Paranoid schizophrenia—A sibling's story, 22:557
First person account: Schizophrenia, 22:727
First person account: Social, economic, and medical effects of schizophrenia, 22:183
First person account: The end of two roads, 23:163

Substance abuse
Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637
Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorder, 23:187
Foreword, 23:179
HIV/AIDS risks as a consequence of schizophrenia, 23:675
Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239
Medical comorbidity in schizophrenia, 22:413
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229
Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215
Substance abuse and schizophrenia: Editors' introduction, 23:181
Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Substantia nigra. See Neuroanatomy

Subtypes of schizophrenia
Cognitive inhibition and schizophrenic symptom subgroups, 22:139
Identifying subtypes of schizophrenia by cluster analyses, 22:545

Supersensitivity
Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Suppressive agents
Treatment of tardive dyskinesia, 23:583

Symptoms. See also Positive symptoms; Negative symptoms; specific symptoms
Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305
Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

T

Tardive dyskinesia
Medical complications of new antipsychotic drugs, 22:475
Treatment of tardive dyskinesia, 23:583

Teacher ratings
Childhood behavior precursors of schizotypal personality disorder, 23:93
Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Thalamus. See Neuroanatomy; Neuropathology

Therapeutic impacts
What do relatives of people with schizophrenia find helpful about family intervention?, 23:341

Therapy. See Pharmacotherapy

Thought disorder
A cognitive neuroscience view of schizophrenic thought disorder, 23:29
Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273
Perseveration in schizophrenia, 23:63

Treatment. See also Pharmacotherapy; specific treatment by name
Clozapine eligibility among State hospital patients, 22:15
The evaluation and treatment of first-episode psychosis, 23:653

First person account: Meaning of psychoses, 23:541

Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Treatment of tardive dyskinesia, 23:583

Treatment compliance

- Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Neuroleptic intolerance, 23:567

Treatment complications

- Medical complications of new anti-psychotic drugs, 22:475

Treatment delay

- EPPIC: An evolving system of early detection and optimal management, 22:305

Treatment-resistant patients

- Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563
- Clozapine eligibility among State hospital patients, 22:15
- Convulsive therapy in schizophrenia?, 22:27

Evaluation of treatment-resistant schizophrenia, 23:663

U

Urinary problems

- Neuroleptic intolerance, 23:567

V

Ventral tegmental area. *See* Neuroanatomy

Violence

- Evaluation of treatment-resistant schizophrenia, 23:663
- Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685
- Psychosis and violence: The case for a content analysis of psychotic experience, 22:91

Viral infections. *See also* Prenatal infections

- Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Voice acoustics

- Speech fluency and schizophrenic negative signs, 23:171

Vulnerability factors. *See also* Risk factors

- Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223
- Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

Smoking and vulnerability for schizophrenia, 22:405

W

Wechsler Adult Intelligence Scale—Revised

- Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Weight gain

- Medical complications of new anti-psychotic drugs, 22:475

Withdrawal effects

- Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, 22:591
- Medication-free intervals and schizophrenia research: Editors' introduction, 23:1
- Research in schizophrenia and the discontinuation of antipsychotic medications, 23:3
- The risk of medication-free research, 23:11

Words Span Forward

- Frontal/executive impairments in schizophrenia, 22:125

Work. *See* Employment

Working memory

- Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437